Sullivan J P, Connor J R, Shearer B G, Burch R M
Nova Pharmaceutical Corporation, Baltimore, Maryland 21224.
Mol Pharmacol. 1992 Jan;41(1):38-44.
NPC 15437 is a prototype member of a new class of synthetically derived protein kinase C (PKC) inhibitors. PKC activity and binding of phorbol ester to the enzyme were inhibited by NPC 15437, with IC50 values of 19 +/- 2 microM and 23 +/- 4 microM, respectively. No inhibition of cAMP-dependent or calcium/calmodulin-dependent protein kinases was observed at concentrations of NPC 15437 up to 300 microM. To investigate the mechanism by which NPC 15437 exerts its effects, a kinetic analysis of the inhibition with respect to three activators of the enzyme, phosphatidylserine, calcium, and phorbol ester, was performed. NPC 15437 was a competitive inhibitor of the activation of PKC by phorbol ester (Ki = 5 +/- 3 microM). Stimulation of PKC alpha by phosphatidylserine was competitively inhibited by NPC 15437 (Ki = 12 +/- 4 microM). The inhibition was mixed with respect to activation by calcium. These results suggest that NPC 15437 is a selective inhibitor of PKC, interacting at the regulatory region of the enzyme. NPC 15437 inhibited PKC in intact cells, dose-dependently antagonizing the phorbol ester-induced phosphorylation of a 47-kDa protein in human platelets.
NPC 15437是一类新的合成衍生蛋白激酶C(PKC)抑制剂的原型成员。NPC 15437可抑制PKC活性以及佛波酯与该酶的结合,其IC50值分别为19±2微摩尔/升和23±4微摩尔/升。在NPC 15437浓度高达300微摩尔/升时,未观察到对环磷酸腺苷(cAMP)依赖性蛋白激酶或钙/钙调蛋白依赖性蛋白激酶的抑制作用。为了研究NPC 15437发挥作用的机制,针对该酶的三种激活剂磷脂酰丝氨酸、钙和佛波酯进行了抑制作用的动力学分析。NPC 15437是佛波酯激活PKC的竞争性抑制剂(Ki = 5±3微摩尔/升)。NPC 15437竞争性抑制磷脂酰丝氨酸对PKCα的刺激作用(Ki = 12±4微摩尔/升)。对于钙激活而言,这种抑制作用属于混合型。这些结果表明,NPC 15437是PKC的选择性抑制剂,在该酶的调节区域发挥作用。NPC 15437在完整细胞中抑制PKC,剂量依赖性地拮抗佛波酯诱导的人血小板中一种47 kDa蛋白的磷酸化。